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Abstract
The link between ankylosing spondylitis and inflammatory bowel disease is unclear, however it is hypothesized that there is a causal 
link between the inheritance of a human leukocyte antigen B27 allele and the development of inflammatory bowel disease symptoms in 
ankylosing spondylitis patients. Research articles assessing the relationship between ankylosing spondylitis, inflammatory bowel disease 
and the human leukocyte antigen B27 antigen were collected from the PubMed database. Patients expressing the human leukocyte anti-
gen B27 allele have a demonstrated predisposition to developing symptoms of inflammatory bowel disease and sacroiliitis in ankylosing 
spondylitis. However, human leukocyte antigen B27 is considered to be just a contributing factor in the disease, as interleukin-23, natural 
killer cells, and alterations to the microbiome have also demonstrated an active role in the development of symptoms. More longitudinal 
studies using larger cohorts are needed to further substantiate a direct causal relationship between ankylosing spondylitis and inflam-
matory bowel disease.
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Introduction
Ankylosing spondylitis (AS) is a debilitating disease found in 
0.5% of the population.1 It is commonly diagnosed in young 
Caucasian men aged 20-40 and is characterized by sacroiliitis 
and fusion of vertebrae. AS is classified as a seronegative ar-
thropathy, which are arthropathies that involve the axial skele-
ton and are negative for rheumatoid factor. Other arthropathies 
include: psoriatic arthritis, reactive arthritis, and enteropathic 
arthritis. Diagnosis of AS is commonly delayed by 5–6 years due 
to the lack of specific biomarkers and variation in clinical pre-
sentation.2 Better understanding of the candidate genes and 
pathogenesis of this incapacitating disease will hopefully result 
in earlier diagnosis and more targeted treatment.
AS patients most commonly present with uveitis, aortitis or 
inflammatory bowel disease (IBD) in addition to classic symp-
toms of chronic lower back pain. Development of uveitis in AS 
patients appears to be correlated with disease duration, the 
theory being that chronic inflammation and immune disruption 
in AS leaves the patient more vulnerable to developing uveitis.3 
However, the co-presentation of IBD and AS appears to be less 
chronological.
Only 5–10 % of AS patients present with overt IBD; conversely 
upwards of 60% of AS patients have subclinical gut inflam-
mation when investigated through more invasive means such 
as ileocolonoscopy.4-6 One study found that nearly all patients 
with regional enteritis, along with the human leukocyte anti-
gen (HLA-B27) allele, were prone to developing AS.7 Numerous 
studies have further demonstrated the close relation between 
IBD and AS.8,9 Both of these diseases are currently posited as 
being autoimmune in etiology, and share some similar genes of 
interest such as IL-23.10 Furthermore, signs of gut inflammation 
are seen prior to the diagnosis of AS and thus may play a role 
in the etiologic pathway.3 
AS has a strong genetic link.11,12 More than 90% of AS patients 
have the HLA-B27 allele, but its role in the underlying etiology 
remains unclear. There appears to be an interplay between not 
only the HLA-B27 genetic predisposition, but other genes, en-
vironmental and immunological factors. These will be outlined 
below and in Figure 1. 
Genetics
HLA-B27 is a major histocompatibility complex (MHC) class 1 
antigen that has an established link with AS. It plays a role 
in presenting self-antigens to T cells. Research suggests that 
misfolding of the protein encoded by this allele leads to its 
accumulation in the endoplasmic reticulum (ER).4 This intra-
cellular accumulation may then precipitate an inflammatory 
response seen both in the joints and in extra-articular sites of 
AS patients. 
Recent Genome Wide Associated Studies (GWAS) have discove-
red two prospective pathways in the etiology of AS—interleukin 
23/T-helper 17 cell (IL23/Th17) and endoplasmic reticulum ami-
nopeptidase-1 (ERAP-1). IL23 is produced by antigen presenting 
cells and is responsible for upregulating Th17 cells.13 Th17 cells 
produce pro-inflammatory cytokines (IL17, IL22, TNF-alpha) and 
are linked to the development of autoimmune diseases.14 Hi-
gher levels of Th17 cytokines have been measured in AS pa-
tients, and anti-TNF-alpha therapy has been shown to down-
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regulate this cell population and provides beneficial therapy 
for AS patients.14,15 An upregulation in the Th17 pathway also 
results in a reciprocal down-regulation in the regulatory T cell 
(Treg) pathway, which normally protects against autoimmune 
disease.16 The level of evidence supporting the role of the Th17 
pathway in AS pathogenesis continues to increase—there have 
been similar findings in animal models and most recently with 
therapeutic monoclonal antibodies.17,18
The second pathway of interest is endoplasmic reticulum ami-
nopeptidase 1 (ERAP-1), an aminopeptidase responsible for 
cleaving peptides in the ER before they are loaded into the 
MHC1. Recent observation demonstrates that ERAP-1 alterations 
only influence AS patients that are HLA-B27 positive.19 Patients 
with higher aminopeptidase activity have altered expression 
of free heavy chains (FHC) on the surface of their circulating 
monocytes. FHC’s are commonly referred to as class one mo-
lecules without the B2 microglobulin.20 These FHC dimers are 
recognized on the surface by inhibitory killing immunoglobulin 
receptors (KIR) of NK cells, and will be further discussed in the 
Immune section.21
 
Environment
Alterations in gut microbiota is suspected of playing a role in 
gut inflammation in AS pathogenesis. Previous studies have 
shown molecular similarities between HLA-B27 and Klebsiella 
pneumoniae.22 Klebsiella and anti-Klebsiella antibodies have 
been isolated from the bowels of patients with active AS and 
parallel exacerbations were seen between Klebsiella levels and 
IBD symptoms.22-24 
It is hypothesized that long-term inflammation of the intesti-
nal mucosa caused by bacterial infections could eventually ca-
talyze an inflammatory response within the joint. However, live 
bacteria have never been isolated from the synovium and chro-
nic anti-bacterial treatment has been futile at slowing disease 
progression. A recent study suggests that, more conceivably, T 
cells are primed in the gut and then migrate to the synovium.24 
Once in the synovium, cluster differentiation 163 (CD163) ma-
crophages are activated and release a very specific cytokine 
profile, including high TNF-alpha and low IL10.25
Immune system
AS patients have shown increased permeability in the muco-
sal lining of their gastrointestinal tract, which is considered a 
first line, innate immune defense.26 E-cadherin, an epithelial 
junctional protein, may contribute to this mucosal disturban-
ce. The down-regulation of E-cadherin is commonly associated 
with cancer metastasis, however, there has been recent proof 
of higher levels of this adhesion complex in patients with IBD 
and spondyloarthropathies.27 
Alteration in the expression of Toll-like receptors (TLR4 and 
TLR2) in the gut mucosa as well as the synovium of patients 
with AS could indicate a link between the innate immune sys-
tem and presentation of IBD in AS.28,29 TLR’s are a family of 
membrane proteins that, when bound by a pathogen associa-
ted molecular pattern (PAMP), activate a pathway that media-
tes inflammation. This pathway is essential in the initiation of 
host defense. After TNF-alpha inhibitor therapy, down-regula-
tion of TLR-4 and remittance of symptoms was observed which 
suggests a prominent role of this protein in AS and potential 
contribution to the etiology.28
A final immune regulatory mechanism that has been suggested 
is the alteration in natural killer (NK) cell defense. Killer immu-
noglobulin-like receptors (KIR) are found predominantly on NK 
cells, T cells and minor subsets of CD4 and CD8 cells. They act 
by binding to MHC class 1 and altering the cytokine profile to 
promote survival of the cell.30 KIR’s are unique as they have 
the ability to recognize different HLA-class one allotypes, which 
could be linked to the AS association with HLA-B27. Haroon 
et al, 2012, demonstrated an increased risk associated with 
KIR3DL2 and a protective effect of KIRDL1.31 To date, KIRDL1 is 
the only KIR known to recognize and bind to the HLA-B alle-
les.32 Therefore, alterations to KIR expression could alter innate 
immune mechanisms of defense, predisposing patients to de-
velopment of AS. 
Current literature reveals a consistent genetic link between AS 
and HLA-B27, however further research has demonstrated that 
this is a very complex, multifactorial and oligogenic disease. 
The association of certain genes with disease is a first step in 
a full understanding of etiology, and current research aims to 
understand the sequence of pathogenesis to develop more tar-
geted therapy. This paper will further explore the relationship 
of HLA-B27 with the extra-articular symptoms of IBD in AS. It is 
hypothesized that there is a causal link between the inheritan-
ce of an HLA-B27 allele and the development of IBD symptoms 
in AS patients. 
Search Strategy and Selection Criteria
The PubMed database (01 January 2004 – 30 December 2014) 
was searched using the terms: “Ankylosing Spondylitis”, “In-
flammatory Bowel Disease” and “HLA-B27 Antigen”. These ter-
ms were searched both as basic terms and “MeSH” terms. 
The author examined the titles and abstracts for articles that 
included: (1) Both IBD and Ankylosing Spondylitis in the abs-
tract; (2) Human subjects, (3) Published in English, (4) Full 
reports (not just abstracts) and (5) Addressed the link and/or 
etiology of IBD and AS. Articles that did not meet these criteria 
were excluded. Full text articles were obtained and classified 
according to their study type. Articles included in the review 
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Figure 1. Major Contributors to the Development of Ankylosing Spondylitis
HLAB27=human leukocyte antigen B27; IL23=interleukin 23; Th17=T helper cell 17; T reg cell=T regulatory 
cell; TLR2=Toll-like Receptor 2; KIR=Killing Inhibitory Receptor; NK=Natural Killer cells.
The International Journal of Medical StudentsInt J Med Students   •   2016  |  May-Aug  |  Vol  4  |  Issue 2 57
Review
can be found in Table 1. Studies were classified using the evi-
dence table created by the authors, as shown in Table 2. The 
methodology used for reviewing articles for inclusion is outli-
ned in Figure 2.
Search Results
Using the search criteria as outlined in the methods, the litera-
ture search provided 226 articles, all of which were reviewed. 
Based on the exclusion criteria, 10 of these articles were inclu-
ded for the purposes of this review. These 10 articles included 
six level-three case-control studies and four level-four cohort 
studies without controls. A summary of candidate genes and 
biomarkers which will be outlined in this review is available 
in Table 3.
Genetics
Ciccia et al (2014) investigated the mechanism of IL23 expres-
sion in a study of 30 HLA-B27 positive AS patients, 15 Crohn’s 
Disease (CD) and 10 normal subjects.13 Sequential gut biopsies 
were taken from the subjects, then autophagy and unfolded 
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Study Study Design
Level of 
Evidence
Study Population Therapy or Exposure Outcomes and Results
Ciccia et al 
(2014)
Case control 
with controls
3 30 AS patients (human 
leukocyte antigen 
(HLA-B27+)); 15 Crohn’s 
disease (CD) patients & 
10 normal subjects
Consecutive gut biopsies were 
analyzed for evidence of misfolding 
of HLA-B27. Unfolded protein 
response (UPR) and autophagy were 
assessed via RT-PCR and IHC. This 
was then compared to the regulation 
of IL-23 expression on lamina propria 
mononuclear cells (LPMCs).
Upregulation of autophagy genes were observed 
in AS and CD patients. Autophagy was also 
required to modulate expression of LPMCs. This 
suggests that misfolding of HLA-B27 occurs in 
the gut of AS patients and in accompanied by 
the activation of autophagy. Autophagy (not 
UPR) is associated with the increased expres-
sion of IL-23 in AS patients.
Duarte et al 
(2014)
Prospective 
Cohort
3 1424 patients; 235 with 
disease onset before 16 
years old
Analyze the characteristics of juveni-
le-onset spondyloarthritis (SpA) (<16 
yr) with a group of adult-onset SpA 
patients.
Juvenile-Onset was characterized by male gen-
der, peripheral involvement (arthritis), positive 
HLA-B27 vs adult-onset was associated with 
inflammatory bowel disease, dactylitis and nail 
involvement.
Wei et al 
(2013)
Case control 3 475 AS patients; 475 
healthy subjects in a 
Taiwanese population
Investigating loci other than endo-
plasmic reticulum aminopeptidase-1 
(ERAP-1) and HLA-B27 for AS suscep-
tibility. A recent GWAS showed two 
potential loci 5q14.3 and 12q12.
The two markers showed no association 
between polymorphisms and AS susceptibility, 
however significant association was seen be-
tween 12q12 and inflammatory bowel disease.
Matzkies et 
al (2012)
Case control 3 39 AS patients; 42 con-
trols. Average age 47, 
average age duration 
was 22 years
Sera were tested by ELISA for 
IBD-associated serologies (ANCA, 
anti-Cerevisiae Ab IgG & IgA, Anti-I2, 
Anti-OmpC and anti-CBir1). BASDAI 
was also completed for AS patients.
Cal protectin levels were elevated in 41% of AS 
patients. fCAL-positive AS patients displayed 
higher IBD antibodies. Further studies needed to 
determine whether fCAL can be used to identify 
a subgroup of AS patients with IBD.
Skare et al 
(2012)
Cross sectional 4 1318 SpA patients; 65% 
white; 31.3% Brazilian; 
3.7% mixed.
65.1% with AS; 18.3% 
psoriatic arthritis, 6.8% 
undifferentiated
Did an array of tests and looked at 
other variables to determine whether 
ethnicity plays a role in the progres-
sion of spondyloarthropathies.
Gender, family history, presence of peripheral 
arthritis and IBD were consistent across all 
three groups. Brazilians had higher MASE score 
and worse performance on the quality of life 
questionnaire.
D’Inca et al 
(2009)
Case control 
with no 
control
4 142 UC patients; 120 CD 
patients
Looked at the prevalence of articular 
pain in IBD patients.
Prevalence of self-reported articular symptoms 
exceeds 40%, with 9.5% incidence in 1 year 
follow up.
Togrol et al 
(2009)
Case control 3 30 AS patients; 19 
age and sex matched 
controls
Analyzed HLA-B27, Anti-gliadin (AGA), 
& endomysial antibodies (EMA). AGA 
positive patients were examined by a 
gastroduodenoscope.
Eleven AS patients were AGA positive (0 
controls); 3 were also EMA positive. Destruction 
of villi was seen the in three AGA/EMA positive 
patients. AGA positivity might contribute to 
pathogenesis of AS (increasing intestinal per-
meability), more research is required.
Orchard et 
al (2008)
Cross sectional 4 44 CD patients Clinical evaluation of symptom ques-
tionnaire, rheumatological exam, HLA 
genotyping, MRI of sacroiliac joints.
40% of patients had evidence of sacroiliitis, 5 
fulfilled the criteria for AS. No association of HLA 
with sacroilitis, but definitely with AS. Posses-
sion of HLA-B27 conveys an increased risk of 
developing axial inflammation in CD.
Aydin et al 
(2008)
Case control 3 175 patients with AS; 
47 with undifferentia-
ted SpA; 103 healthy 
controls
Questioned for demographic features, 
BASDAI scores, BASRI and mSASSS 
scores were acquired; Anti-Saccho-
romyces Cervesiae Antibodies (ASCA) 
was measured with ELISA.
Increased prevalence of ASCA in AS and undi-
fferentiated SpA. ASCA can also be a marker for 
radiological damage and more severe course AS.
Turkcapar 
et al (2006)
Case control 
with no 
control
4 162 with IBD Complete rheumatological examina-
tion, evaluated via the ESSG criteria 
for SpA. Analyzed HLAB27, B51 & 
ANCA.
Prevalence of SpA and AS in IBD – 45.7% & 9.9%. 
High prevalence of asymptomatic sacroiliitis in 
IBD, an early diagnosis of inflammatory arthritis 
could prevent a disability due to SpA and AS.
BASDAI=Bath Ankylosing Spondylitis Disease Activity Index; BASRI=Bath Ankylosing Spondylitis Radiology Index; ELISA=enzyme-linked immunosorbent assay; ESSG=Eu-
ropean Spondyloarthropathy Studies Group; GWAS=genome-wide association study; IHC=immunohistochemistry; MASE=Maastricht Ankylosing Spondylitis Enthesitis 
Score; MRI=magnetic resonance imaging; mSASSS=modified Stoke Ankylosing Spondylitis Spinal Score; RT-PCR=reverse transcription polymerase chain reaction.
Table 1. Studies Evaluating the Genetics of Ankylosing Spondylitis
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protein response (UPR) were evaluated in mononuclear cells of 
the lamina propria by reverse transcription polymerase chain 
reaction. The researchers noted upregulation of protein ex-
pression in the autophagy pathway via LC311, ATG5 and ATG12 
(r2=0.66, 0.68, 0.77 respectively, p<0.0001). However, no signi-
ficant expression of UPR genes, namely HSPA5, was observed 
when compared to controls (p<0.0001). This research suggested 
that misfolding of HLA-B27 in the gut mucosa and modulation 
of IL23 is associated with autophagy rather than UPR.
Potential IBD & AS Biomarkers
Anti-Sacchoromyces cervesiae Antibodies (ASCA)
Aydin et al measured anti-Sacchoromyces cervesiae antibodies, 
a characteristic marker of CD, and Bath Ankylosing Spondyli-
tis Disease Activity Index (BASDAI), a common self assessment 
used in AS diagnosis, in 175 AS patients, 47 undifferentiated 
spondyloarthropathy (uSpA) patients, an incomplete or early 
form of a definitive seronegative spondyloarthropathy, and 
103 healthy controls.6 There was an increased prevalence of 
ASCA in patients with AS and uSpA (p<0.0008, p<0.02 respec-
tively), however no correlation was seen between ASCA and 
erythrocyte sedimentation rate (ESR), C-Reactive Protein (CRP) 
and BASDAI scores (p=0.75, 0.79, 0.28 respectively). ASCA-posi-
tive patients also required anti TNF-alpha therapy more often 
(p<0.006). This study failed to show any correlation with ASCA 
and HLA-B27 (p=1). 
Fecal Calprotectin
Matzkies et al conducted a pilot study to measure fecal calpro-
tectin (fCal), a biochemical marker for intestinal wall inflam-
mation, and other IBD-related serology (ASCA, ANCA, anti-OmpC, 
anti-CBir1 and anti-I2) in 39 AS patients and 42 controls.33 AS 
patients were mostly male and 76% were HLA positive. The fCal 
levels were significantly higher in the AS group (p<0.0002), as 
were ANCA, ASCA, and anti-CBir1 (p<0.001, 0.023, 0.003 respec-
tively). The fCal-positive AS patients also demonstrated higher 
titers of IBD antibodies, namely IgA ASCA, IgG ASCA and CBir1 
(p<0.05, 0.003, 0.002 respectively) and higher BASDAI scores 
(p=0.016). However, no correlation was shown between the 
presence of the HLA allele and high fCal levels (p=0.71).
Anti-endomysial (EMA) and Anti-gliadin (AGA) Antibodies
Togrol et al analyzed 30 AS patients and 19 controls with basic 
clinical serology for HLA-B27, AGA and EMA, both IgG and IgA 
antibody subtypes.34 Radiological assessment was also perfor-
med on all subjects. Gastroduodenoscopy was only performed 
on AGA-positive patients. Only 11 of the 30 AS patients were 
positive for AGA (p<0.001), and three of 30 were positive for 
EMA, while none of the controls were positive for either anti-
body. No correlation was found between presence of AGA and 
severity of AS.
Relevance of Ethnicity
Skare et al evaluated 1318 consecutive patients with spond-
yloarthropathies (SpA), in 29 different referral centers throu-
ghout Brazil.35 They compared and contrasted the disease 
expressivity and variance of SpA among different ethnic bac-
kgrounds. This was achieved through a standard protocol of 
investigation outlined by the researchers, whereby information 
was retrieved from patient interviews and multiple self-assess-
ment scores (BASDAI, BASFI, AS quality of life questionnaire 
etc.). The physical exam was guided through many standar-
dized scores and activity indices, such as the Bath Ankylo-
sing Spondylitis Metrology Index (BASMI) and the Maastricht 
Ankylosing Spondylitis Enthesitis Score (MASES). In the cohort, 
65% of patients were white (compared to the general popula-
tion of 48.7%), 31% were African-Brazilian and 3.7% were of 
other ethnicities. White patients presented with more psoria-
sis and linkage to HLA-B27 (p=0.002, 0.014 respectively). Afri-
can-Brazilian patients reported worse back pain and hip in-
volvement (p=0.041, 0.020 respectively) in addition to a lower 
patient global assessment and a lower quality of life (p=0.011, 
<0.0001 respectively). HLA-negative patients were characterized 
as having no family history, later disease onset and limited 
extra-articular manifestations. However, no statistical data was 
provided for these statements.
Rivington J, et al. Establishing a Causal Link between Ankylosing Spondylitis and Inflammatory Bowel Disease
0 Preclinical studies– including experimental studies and animal models
1 Randomized controlled trials
2 Non-randomized controlled trial – a prospective (pre-planned) study with a predetermined eligibility criteria and outcome measures
3 Observational studies with controls- includes retrospective, case-control studies, and cohort studies
4 Observational studies without controls – includes cohort studies without controls, case series without controls, case studies without control
Table 2. Criteria Used to Evaluate Study Quality
Figure 2. Flow Diagram for Article Selection
PubMed Search
"Ankylosing Spondylitis" + "Inflammatory 
Bowel Disease" + "HLA-B27 Antigen"
N=226
Full-text articles reviewed
N=226
Articles included in the review
N=10
Excluded because the following inclusion 
criteria were not met:
• Contained "ankylosing spondylitis" and 
"inflammatory bowel disease" in the 
abstract
• Human subjects
• Published in English
• Full reports (not just abstracts)
• Addressed link and/or etiology of 
ankylosing spondylitis and inflammatory 
bowel disease
N=216
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A second ethnic study, conducted by Wei et al (2013) inves-
tigated genes unveiled in the European based genome-wide 
association study of AS, specifically EDIL3, HAPLN1 and ANO6 
at 12q12 and their association to AS.36 The study included 475 
AS patients and 475 controls, 90.7% of the AS patients were 
HLA-B27-positive. They used genetic markers for the relevant 
genes, along with multiple AS activity indices and relevant 
physical exam findings to compare patients. In the Taiwanese 
population, EDIL3, HAPLN1 and ANO6 demonstrated no link to 
AS (p=0.3033, 0.6754, 0.5266 respectively), however there was a 
significant association found between ANO6 and IBD (p=0.0131). 
IBD Patients with Joint Manifestations
Turkcapar et al evaluated 162 adult patients with either Crohn's 
disease (CD) or ulcerative colitis (UC) for spondyloarthropathy 
(SpA) by a full rheumatological assessment and radiography.2 
HLA-B27, B51 and anti-neutrophil cytoplasmic antigen (ANCA) 
were also tested in all patients. The prevalence of IBD and 
SpA was 45.7%. They found that the HLA-B27 allele was more 
common in the patients with sacroiliitis, peripheral arthritis 
and enthesitis (p<0.001 for all). Additionally, 13.6% of patients 
exhibited no musculoskeletal manifestations on physical exa-
mination, but were determined to have grade-2 sacroiliitis on 
computer tomography (CT) and radiographs. 
Another study by Orchard et al (2009) investigated 44 patients 
with CD in a prospective study.7 They evaluated the patients’ 
presenting symptoms, rheumatology profile and HLA status 
and conducted a radiologic evaluation of the patients’ sacroi-
liac joints. The researchers found that 17 of the 44 patients 
had evidence of sacroiliitis, HLA-B27 was present in seven of 
44 patients (15.9%), all of whom had sacroiliitis and five of 
whom had AS (p<0.001). Sacroiliitis appeared to be a common 
extra-intestinal manifestation of CD, but HLA-B27 was not asso-
ciated with isolated sacroiliitis (p=0.057). Conversely, HLA-B27 
could be considered an important risk factor for developing 
axial SpA in CD, as 100% of patients with this allele in this 
study developed sacroiliitis.
In a final IBD study, D’Inca et al surveyed 651 patients over a 
12-month period to determine which extra-intestinal symptoms 
were apparent in IBD patients.37 Articular pain was reported 
most frequently, totaling 262 patients, specifically 142 patients 
with UC and 120 patients with CD. These 262 patients were 
further evaluated by rheumatologists for HLA type, degree of 
joint involvement (axial or peripheral) and followed up 12 mon-
ths after the initial survey. HLA-B27 was present in five of the 
participants, three of whom had AS. The frequency of HLA-B27 
was significantly higher in the subgroup of patients with axial 
arthropathy compared to peripheral arthropathy (OR = 13.1, 
p<0.00001). Arthropathies were axial in 53%, and polyarticular 
in 23% of patients. Of the 40.2% of patients who reported ar-
thralgia in the original survey, only 9.5% reported symptoms 
during the 12-month follow up.
Discussion
In this review, the relationship between IBD and AS was exami-
ned. There is a significant overlap between these two diseases, 
with IBD being the most common extra-articular symptom in AS 
and arthralgia being the most common extra-intestinal symp-
tom in IBD. It nevertheless remains questionable whether there 
is a causal relationship between IBD and AS. It is apparent 
that the inheritance of HLA-B27 does not definitively determine 
whether a person will develop AS, as only 1-2% of the popu-
lation that is HLA-B27 positive ends up developing AS. There 
is, however, a more significant link between the presence of 
the HLA-B27 allele and a concurrent diagnosis of IBD. Studies 
show that the majority of patients with IBD and the HLA-B27 
allele will also present with sacroiliitis.7 They suggest that gut 
inflammation in combination with HLA-B27 almost guarantees a 
subsequent diagnosis of AS.
Many of the studies included in this review used a cross-sectio-
nal design, which limits the interpretation of causal relations-
hips in AS.35,36 It allows the researchers to note associations 
but denies the ability to sequence events in disease etiology. 
A Brazilian study juxtaposes epidemiologic variables between 
two age groups: juvenile (younger than 16 years of age) and 
adult-onset (greater than 16 years of age) spondyloarthropathy. 
Findings indicate that male gender and HLA-B27 are more com-
mon in younger patients, whereas IBD and cutaneous psoriasis 
are more common in adult-onset SpA. One could extrapola-
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Candidate Genes/
Biomarkers
Relevance Future direction
HLA-B27 90% link to AS. Current understanding: Misfolding 
of B2 leads to intracellular accumulation → stress/
inflammatory response
More research needed to understand the exact mechanism
IL23/Th17 Upregulation of Th17 cells via IL23 → development 
of autoimmune conditions
Considered to be a gene of current major research interest. Overlap seen 
between AS and IBD pathogenesis. May indicate autoimmune mechanism
ERAP-1 Aids in cleaving peptides for MHC1 loading Second strongest association with AS. Requires further investigation of link 
with NK cells
ASCA Currently used in cystic fibrosis and liver cirrhosis Extensive variability in the literature. More sensitive and specific assays 
required
fCal Higher titers found in patients with IBD symptoms Inconclusive. Consider conducting case control studies with patients on 
TNF inhibitor & NSAID therapy
AGA & anti-EMA Currently used in celiac disease Postulated as increasing intestinal permeability. Further research is 
required
Table 3. Candidate Genes and Biomarkers Outlined in This Review
HLAB27=human leukocyte antigen B27; Th17=T helper 17 cells; IL23=interleukin-23; ERAP-1=endoplasmic reticulum aminopeptidase-1; ASCA=anti-Sacchoromy-
ces cervesiae antibodies; EMA=anti-endomysial antibodies; AGA=anti-gliadin antibodies; fCal=fecal calprotectin.
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te from this study that IBD is a latter manifestation of SpA, 
however this is a cross-sectional design.37 Further longitudinal 
investigations that evaluate associations between genetic and 
environmental risk factors would contribute immensely to un-
derstanding the complete pathogenesis. 
The advantage of cross-sectional studies is that researchers 
can reach a more diverse population and may also expose as-
sociations that serve as a starting point for other, more focused 
studies. This was observed in the two studies that analyzed 
the effect of ethnicity on the clinical presentation of AS. One 
unveiled the difference in candidate gene expression seen in 
European versus Taiwanese populations, whereas the other hi-
ghlighted the variation in symptoms among different ethnici-
ties in Brazil.35,36 The results of these studies suggest that the 
pathogenesis for AS may be unique in each ethnic group and 
that GWAS conducted in one population is not transferable to 
another. Further evidence of this was demonstrated by one re-
searcher who noted that the HLA-B27 allele was found in 80% of 
white patients compared to 60% of black patients.35 Countries 
with a mixed demographic may need to take this into consi-
deration when conducting studies or determining treatment 
options for patients from different ethnic backgrounds. 
Many studies included in this review involved a sample popu-
lation that was identified based on a recent visit to the rheu-
matologist.7,33,34,36 However, many developing nations do not 
have equal access to health care, therefore, patients involved 
in these studies may be more representative of urban or higher 
social class.35 It is, therefore, critical that adequate represen-
tation from all social demographics be included in studies, to 
gain the best possible understanding of disease manifestation 
and treatment protocol. 
Another shortcoming of many studies is the small sample size 
and concomitant lack of statistical power. Determinants of sta-
tistical power include sample size, statistical significance cri-
teria (p-values) and magnitude of effect. One study referenced 
an odds ratio of 13.1 and p<0.00001 with regard to the HLA-B27 
allele and the symptoms of axial arthropathy.38 Both of these 
values exhibit undeniable statistical significance. However, this 
result was based on a mere five patients in the study with 
HLA-B27. Despite the statistical significance of this study, the 
small sample size raises questions about the applicability of 
the results to the broader population. Similarly, other studies 
had sample groups with fewer than 40 participants.33,34 Larger 
studies are required to determine concrete relationships.
Multiple studies have investigated the use of selective biomar-
kers in AS patients.6,33,34 The diagnosis of AS is currently made 
through a combination of physical examination, history and 
radiography, however, due to the mixed clinical presentation 
and delayed evidence on radiography, AS is commonly mis-
diagnosed or delayed in diagnosis by 5-6 years.2 Accurate and 
early diagnosis of the disease would allow a treatment regime 
designed to delay fusion of vertebrae, stiffening of joints and 
debilitating effects of AS. Biomarkers would allow for more pre-
cise direction with prognosis and management.39
The anti-ASCA antibody showed higher titers in patients with 
more symptoms of AS, but no correlation with the HLA-B27 alle-
le. Anti-ASCA is also used in the evaluation of patients with liver 
cirrhosis, cystic fibrosis and Behcet’s disease.6 There appears 
to be extensive variability in the literature as some studies de-
monstrated no correlation between anti-ASCA and SpA, others 
limit the association to IgA not IgG, and some claim it is seen in 
AS but not uSpA.40-42 The discrepancy of results may be due to 
the variation in sensitivity and specificity in assays. More con-
sistent and reproducible results need to be established before 
anti-ASCA could be considered a valid biomarker for AS. 
Another biomarker, fCal, showed higher titers in patients with 
IBD symptoms, but no relevant association to the HLA allele.33 
This study purposely excluded patients that were on TNF-alpha 
inhibitor or non-steroidal anti-Inflammatory drugs (NSAID), with 
the consideration that NSAIDS can increase gut permeability 
and that TNF inhibitors may alter gut inflammation.33 Other stu-
dies that investigated fCal did not use these exclusion criteria 
and concluded that there was no correlation between fCal and 
gut inflammation, and high levels of fCal were associated with 
age, disease duration, raised ESR and serum calprotectin levels, 
but not with GI symptoms.43 This exclusion criterion may limit 
the applicability of results to the general population, as most 
patients with AS or underlying gut pathology will likely be on 
some sort of therapy. The exclusion of this demographic from 
the study, therefore, reduces the relevance and application of 
the results in the clinical setting. Future studies may consider 
evaluating the levels of fCal in both the presence and absence 
of TNF inhibitors and NSAIDS to gain a better understanding of 
how this marker fluctuates with treatment regimen and fla-
re-ups of IBD.
The final biomarkers uncovered in this review were anti-AGA 
and anti-EMA, two antibodies commonly used in celiac disea-
se. Researchers determined that anti-AGA was higher in the 
AS group, and also found that three patients who were an-
ti-EMA-positive were also anti-AGA-positive. This study lacked 
statistical power as it analyzed only 30 patients. Its analysis 
was skewed, as gastroduodenoscopy and mucosal biopsy was 
only performed on the 11 patients who were AGA positive, whe-
reas all other negative anti-AGA patients in the AS group and 
the entire control group were limited to serological analysis. 
Researchers claim that increased inflammatory cell infiltrate 
was seen in the lamina propria of anti-AGA/EMA-positive pa-
tients. However, they did not have a control group for compari-
son. Anti-AGA antibodies may be an indicator of AS pathogene-
sis by increasing intestinal permeability, but it does not appear 
to be specific to AS as only 11 of 30 patients had a positive 
titer. A larger cohort is required to validate these associations. 
Current research is heavily focused on understanding the ge-
netic link to AS and how certain genes play a role in the pa-
thogenesis, but not necessarily on the exact link between the 
symptoms of IBD and AS. A limitation to this review is that it is 
based on a key word search of the literature, and although IBD 
and HLA-B27 are brought up consistently in research relating 
to AS, it is uncommon to find a directed study on the relation 
between the two. However, this is an inherent limitation of the 
searching capability of research databases. An example of this 
can be seen in the three studies included in this review, all 
of which targeted a population of subjects with IBD, but then 
looked at the prevalence of associated arthralgia.2,7,38 Converse-
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ly, the main goal of this paper was to do the opposite: evaluate 
the likelihood of AS patients having symptoms of IBD. Given 
that this kind of study provides the greatest insights regar-
ding this relationship to date, more directed studies looking 
specifically at AS patients need to be undertaken for a clear 
consensus to be reached. 
Future Directions
Pharmaceuticals
Current treatment of AS includes both pharmacological and 
non-pharmacological approaches. Pharmacological intervention 
normally includes NSAIDS, disease modifying anti-rheumatic 
drugs (DMARDS) and TNF-alpha inhibitors. Review of TNF-alpha 
inhibitor therapy has demonstrated that 40% of AS patients ex-
perience an increase in function, reduction in pain and morning 
stiffness and overall well-being.44 Further advances in pharma-
cologic treatment are limited to a full comprehension of AS pa-
thogenesis, predisposing genes and environmental factors, as 
this enables manufacturers to target more disease-specific cul-
prits. As an example, the more conclusive evidence of IL23R’s 
role in AS has allowed researchers to manufacture an IL23 spe-
cific monoclonal antibody which is currently undergoing phase 
two clinical trials.18
Genetics
Studies have confirmed the role of IL23R in AS aetiopathogene-
sis, and suggested that this pathway may be a key regulator in 
the misfolding of the HLA-B27 protein.13 Previous studies sug-
gested that misfolding was due to an unfolded protein respon-
se (UPR) in the cell, however this study proved that it was due 
to upregulation of autophagy. Additionally, they localized the 
misfolding of HLA-B27 to the gut, which further confirms the 
suspicion that chronic gut inflammation may be a contributor 
to the early pathogenesis of AS.
Other genes such as ERAP were not discussed in this review, 
as they did not appear in the search criteria. The development 
of AS is multifactorial and may even be unique in each patient, 
therefore, careful accreditation of all genetic markers unveiled 
in the GWAS is necessary in future research.
GIT Therapy
Not all AS patients suffer from IBD, but a large majority have 
subclinical gut inflammation. Treatment of this could be a futu-
re consideration for clinicians. Multiple studies have identified 
bacteria such as Klebsiella, Yersinia, and most recently Faecali-
bacterium prausnitzii and Bacteroides fragilis in AS patients.45 
A potential route of treatment is fecal microbiota transfer (FMT) 
– replacement of missing or overbearing bacteria to the natu-
ral multicomponent state. FMT is considered a highly effective 
treatment for Clostridium difficile, and was recently accepted 
by the Food & Drug Administration (FDA) as an experimental 
therapy. It has shown variable effectiveness in the treatment of 
IBD, however, the success in AS is still under review.46 Further-
more, a pediatric study on IBD concluded that certain micro-
biota are more responsive to TNF therapy and that the levels of 
certain bacteria could be used as a predictor of responsiveness 
to TNF therapy.47
An alternative, less invasive, manipulation of the gut microbio-
ta involves the alteration of diet through supplementation and 
probiotics.22 Probiotics improve colitis and IBD symptoms in 
murine models and human subjects due to their induction of 
TLR9 and resulting anti-inflammatory effect.48,49 Adjusting an AS 
patient’s diet could be used as a complement to conventional 
pharmaceuticals in the future. 
Radiography
Due to the variation in clinical presentation, AS is a challenging 
arthropathy to diagnose. It may be possible to diagnose AS 
earlier if younger patients with IBD are screened for signs of 
spondyloarthropathy.2 A full radiological and rheumatological 
assessment could drastically reduce the progression and po-
tential disability of SpA.
Conclusion
This review supplements current evidence that there is a link 
between IBD and AS. Many studies prove the predisposition 
of IBD patients with HLA-B27 to developing symptoms of sa-
croiliitis and AS. However, HLA-B27 is considered to be one of 
many factors in the disease, not the sole contributor. More 
longitudinal studies need to be conducted to clarify whether 
AS and IBD are concomitant or causal of one another. Similarly, 
larger cohorts should be considered to increase the power and 
relevance of the studies. The complex pathogenesis, polygenic 
etiology and variance between ethnicities of AS has proven to 
be an obstacle and major focus of research. The discovery of 
more specific biomarkers is essential for the early diagnosis 
of AS and a deeper understanding of the exact pathogenesis 
will allow for more directed and effective treatment for this 
incapacitating disease.
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